<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576732</url>
  </required_header>
  <id_info>
    <org_study_id>CR014740</org_study_id>
    <secondary_id>RISAUT4002</secondary_id>
    <nct_id>NCT00576732</nct_id>
  </id_info>
  <brief_title>A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder</brief_title>
  <official_title>Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness (change in level of irritability
      and related behaviors) and safety and tolerability of the administration of 2 different fixed
      dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children
      or adolescents who have autism, and to evaluate the safety and tolerability of the drug for
      additional 26 weeks after the initial 6-week study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autistic Disorder is a condition that develops early in childhood and persists throughout
      life. Seventy-five percent of children and adolescents with autistic disorder have
      irritability symptoms such as aggression towards others, deliberate self-injurious behavior,
      temper tantrums, and quickly changing moods. These symptoms affect their daily functioning
      such as school performance, interactions with family members and compliance to treatment.
      Risperidone is an atypical antipsychotic agent that has been recently approved for the
      treatment of irritability associated with Autistic Disorder in children and adolescents aged
      5 to 16 years. The approved dose range is 0.5-3 mg per day. The aim of this study is to
      evaluate the effectiveness (change in level of irritability and related behaviors) of a lower
      dose (0.125 mg or 0.175 mg risperidone per day depending on body weight). The study will
      include three treatment groups. A placebo group, a low dose risperidone group and a higher
      dose risperidone group (1.25 mg or 1.75mg per day depending on body weight). This phase of
      the study will be 6 weeks. During the study, neither investigators nor the patients will be
      told which treatment the patient received. This is called &quot;double blind&quot;. The placebo
      treatment is not expected to be effective. The higher dose group is expected to be effective.
      At the end of the study, data from the lower dose group will be compared to the placebo group
      to see if it is effective. Another aim of this study is to evaluate the safety and
      tolerability of risperidone. At the end of the 6-week double-blind period, patients may enter
      a 6-month open-label period during which all patients will receive risperidone. During this
      phase of the study, the doses can be adjusted to a maximum of 1.25 mg or 1.75mg per day
      depending on body weight. Both investigator and the patient will know what dose the patient
      is taking. About 93 patients will be randomized. The study will be conducted by investigators
      from about 15 clinics. Assessments of effectiveness include the Aberrant Behavior Checklist
      (ABC) subscales including the irritability subscale (ABC-I), the Clinical Global Impression
      of Change (CGI C); the Clinical Global Impression of Severity (CGI-S); the response rate, and
      the Compulsions Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY BOCS).
      Safety evaluations include monitoring of adverse events, physical examinations, clinical
      laboratory tests, nighttime sleep quality and daytime drowsiness, and extrapyramidal symptoms
      (EPS) as assessed using the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia
      Rating Scale (BARS) and the Simpson-Angus Scale (SAS). Venous blood samples will be collected
      for the determination of plasma concentrations of risperidone and 9-hydroxyrisperidone. The
      study hypotheses are that the higher dose level of risperidone is significantly superior to
      placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week 6
      or early withdrawal) and that the lower dose level of risperidone is significantly superior
      to placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week
      6 or early withdrawal). Double-blind phase: Risperidone oral solutions taken once daily.
      Depending on body weight patients take 1.25 mL or 1.75 mL of either a 0.1 mg/mL or a 1.0
      mg/mL risperidone solution or matching placebo, for 6 weeks. Open-label phase: Medication can
      be taken once or twice a day. Starting from 0.125mg or 0.175mg per day, drug levels are
      titrated over 2 weeks to a maximum dose level of 1.25 mg risperidone/day or 1.75 mg /day
      depending on body weight, for 26 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had at Least 25% Improvement in ABC-I</measure>
    <time_frame>6 weeks</time_frame>
    <description>ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression Severity (CGI-S)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1=&quot;not ill&quot;, 2=&quot;very mild&quot;, 3=&quot;mild&quot;, 4=&quot;moderate&quot;, 5=&quot;marked&quot;, 6=&quot;severe&quot;, 7=&quot;extremely severe&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Investigator impression of change over time from double-blind baseline on a 7-point scale (1=&quot;very much improved&quot;, 2=&quot;much improved&quot;, 3=&quot;minimally improved&quot;, 4=&quot;no change&quot;, 5=&quot;minimally worse&quot;, 6=&quot;much worse&quot;, 7=&quot;very much worse&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose (mg/dL) at 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (IR) at 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose (mg/dL) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance (IR) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Autistic Disorder</condition>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone low dose Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) qd or bid for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone high dose Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) qd or bid for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral solution qd or bid for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution qd or bid for 6 weeks</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone high dose</intervention_name>
    <description>Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) qd or bid for 6 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone low dose</intervention_name>
    <description>Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) qd or bid for 6 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of Autistic Disorder (299.00)

          -  ABC-I Subscale score of greater than or equal to 18

          -  CGI-S of greater than or equal to 4

          -  mental age &gt;18 months, body weight of at least 20 kg, seizure-free for at least 6
             consecutive months and if on anticonvulsants must be on a dosage that has been stable
             for at least 4 weeks

          -  Medication free for 1 week before the start of the study for all psychotropic drugs,
             except 4 weeks for fluoxetine and at least 8 weeks for injectable medications

          -  Female patients must be premenarchal or sexually abstinent or, if heterosexually
             active, must practice an effective method of birth control.

        Exclusion Criteria:

          -  History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar
             disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified
             (PDD NOS), Asperger's, or Rett's

          -  Any history of hypersensitivity to risperidone, or its excipients in formulation, or
             other known drug allergy

          -  Patients who received risperidone within 3 months before screening (except p.r.n. use)

          -  Patients who did not demonstrate sufficient clinical response to an adequate trial of
             risperidone treatment in the past (an adequate trial is defined as a period of at
             least 4 weeks at an adequate dose)

          -  Neurologic disorder (e.g., Neuroleptic Malignant Syndrome, seizure disorders that are
             unstable, seizure activity within the past 6 months)

          -  History of alcohol or substance dependence within 3 months of screening

          -  Female subject who is pregnant (positive beta-HCG) or breast feeding

          -  Patients with existing moderate or severe EPS or history of tardive dyskinesia

          -  Patients who have received an experimental drug or used an experimental medical device
             within 3 months before the planned start of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=78&amp;filename=CR014740_CSR.pdf</url>
    <description>A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>September 2, 2010</results_first_submitted>
  <results_first_submitted_qc>September 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2010</results_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritability</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Antipsychotic agent</keyword>
  <keyword>Autism</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Double-blind Period. Oral solution for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Risperidone Low Dose</title>
          <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Risperidone High Dose</title>
          <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo/RIS</title>
          <description>Open-label Period. Subjects in the double-blind placebo group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
        </group>
        <group group_id="P5">
          <title>Ris Low Dose/RIS</title>
          <description>Open-label Period. Subjects in the double-blind risperidone low dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
        </group>
        <group group_id="P6">
          <title>Ris High Dose/RIS</title>
          <description>Open-label Period. Subjects in the double-blind risperidone high dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>DOUBLE BLIND</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>OTHER</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OPEN LABEL</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="30">26 of 27 double-blind placebo completers and 4 of 8 placebo non-completers entered open-label.</participants>
                <participants group_id="P5" count="24">24 of 25 double-blind RIS low dose completers and 0 RIS low dose non-completers entered open-label.</participants>
                <participants group_id="P6" count="25">All 25 double-blind RIS high dose completers and 0 RIS high dose non-completers entered open-label.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>OTHER</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Double-blind Period. Oral solution for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Risperidone Low Dose</title>
          <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Risperidone High Dose</title>
          <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="2.57"/>
                    <measurement group_id="B2" value="10.2" spread="3.42"/>
                    <measurement group_id="B3" value="9.3" spread="3.11"/>
                    <measurement group_id="B4" value="9.3" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States of America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale</title>
        <description>Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale</title>
          <description>Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).</description>
          <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="10.67"/>
                    <measurement group_id="O2" value="-7.4" spread="8.12"/>
                    <measurement group_id="O3" value="-12.4" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A step-down testing procedure was employed with the risperidone high dose versus placebo comparison tested first. If this comparison was significant the risperidone low dose versus placebo comparison would be performed.
A clinically relevant difference in the change from baseline on the ABC Irritability subscale was assumed to be 6 with a standard deviation of 8. To achieve 80% power with Type I error rate of 5%, 93 subjects were required.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Type I error is preserved by the step down procedure, no multiple comparison adjustment is needed. A priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included factors for treatment group, center (after pooling of small centers), baseline weight stratification, and baseline ABC-I value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.19</ci_lower_limit>
            <ci_upper_limit>-3.52</ci_upper_limit>
            <estimate_desc>Mean difference is change in Risperidone high dose arm minus change in placebo arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>Type I error is preserved by the step down procedure, no multiple comparison adjustment is needed. A priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included factors for treatment group, center (after pooling of small centers), baseline weight stratification, and baseline ABC-I value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.36</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Mean difference is change in Risperidone low dose arm minus change in placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had at Least 25% Improvement in ABC-I</title>
        <description>ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).</description>
        <time_frame>6 weeks</time_frame>
        <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had at Least 25% Improvement in ABC-I</title>
          <description>ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).</description>
          <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.817</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression Severity (CGI-S)</title>
        <description>Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1=&quot;not ill&quot;, 2=&quot;very mild&quot;, 3=&quot;mild&quot;, 4=&quot;moderate&quot;, 5=&quot;marked&quot;, 6=&quot;severe&quot;, 7=&quot;extremely severe&quot;).</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression Severity (CGI-S)</title>
          <description>Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1=&quot;not ill&quot;, 2=&quot;very mild&quot;, 3=&quot;mild&quot;, 4=&quot;moderate&quot;, 5=&quot;marked&quot;, 6=&quot;severe&quot;, 7=&quot;extremely severe&quot;).</description>
          <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.79"/>
                    <measurement group_id="O2" value="-0.4" spread="0.73"/>
                    <measurement group_id="O3" value="-1.0" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included factors for treatment group, center (after pooling of small centers), baseline weight stratification, and baseline CGI-S value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
            <estimate_desc>Mean difference is change in Risperidone high dose arm minus change in placebo arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included factors for treatment group, center (after pooling of small centers), baseline weight stratification, and baseline CGI-S value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>Mean difference is change in Risperidone low dose arm minus change in placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.</title>
        <description>Investigator impression of change over time from double-blind baseline on a 7-point scale (1=&quot;very much improved&quot;, 2=&quot;much improved&quot;, 3=&quot;minimally improved&quot;, 4=&quot;no change&quot;, 5=&quot;minimally worse&quot;, 6=&quot;much worse&quot;, 7=&quot;very much worse&quot;).</description>
        <time_frame>6 weeks</time_frame>
        <population>All randomized subjects with at least one dose of study medication and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.</title>
          <description>Investigator impression of change over time from double-blind baseline on a 7-point scale (1=&quot;very much improved&quot;, 2=&quot;much improved&quot;, 3=&quot;minimally improved&quot;, 4=&quot;no change&quot;, 5=&quot;minimally worse&quot;, 6=&quot;much worse&quot;, 7=&quot;very much worse&quot;).</description>
          <population>All randomized subjects with at least one dose of study medication and at least one postbaseline value. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.985</p_value>
            <p_value_desc>P-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test controlling for center (after pooling small centers) and baseline weight stratification.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose (mg/dL) at 6 Weeks</title>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline fasting laboratory samples. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose (mg/dL) at 6 Weeks</title>
          <population>All randomized subjects with at least one dose of study medication and both baseline and at least one postbaseline fasting laboratory samples. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period (Last Observation Carried Forward [LOCF]).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="8.20"/>
                    <measurement group_id="O2" value="-0.1" spread="8.81"/>
                    <measurement group_id="O3" value="-0.3" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance (IR) at 6 Weeks</title>
        <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>All randomized subjects with &gt;=1 dose of study medication and fasting glucose and insulin at baseline and at &gt;=1 postbaseline time point. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period. Means are adjusted for baseline weight (&lt;45 kg, &gt;=45 kg) and baseline IR.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Double-blind Period. Oral solution for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Low Dose</title>
            <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Risperidone High Dose</title>
            <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance (IR) at 6 Weeks</title>
          <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
          <population>All randomized subjects with &gt;=1 dose of study medication and fasting glucose and insulin at baseline and at &gt;=1 postbaseline time point. For subjects who discontinued, Week 6 data is imputed using the subject's last nonmissing, postbaseline value in the double-blind period. Means are adjusted for baseline weight (&lt;45 kg, &gt;=45 kg) and baseline IR.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="-0.34" upper_limit="1.07"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.76" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.45" lower_limit="-0.18" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose (mg/dL) at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>All subjects with at least one dose of study medication in the open label phase and both double-blind baseline and at least one open-label period fasting laboratory samples. For subjects who discontinued, Month 6 data is imputed using the subject's last nonmissing, postbaseline value in the open-label period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/RIS</title>
            <description>Open-label Period. Subjects in the double-blind placebo group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
          <group group_id="O2">
            <title>Ris Low Dose/RIS</title>
            <description>Open-label Period. Subjects in the double-blind risperidone low dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
          <group group_id="O3">
            <title>Ris High Dose/RIS</title>
            <description>Open-label Period. Subjects in the double-blind risperidone high dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose (mg/dL) at 6 Months</title>
          <population>All subjects with at least one dose of study medication in the open label phase and both double-blind baseline and at least one open-label period fasting laboratory samples. For subjects who discontinued, Month 6 data is imputed using the subject's last nonmissing, postbaseline value in the open-label period.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="12.27"/>
                    <measurement group_id="O2" value="3.5" spread="12.26"/>
                    <measurement group_id="O3" value="2.3" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance (IR) at 6 Months</title>
        <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>All subjects with at least one dose of study medication in the open label phase and both double-blind baseline and at least one open-label period fasting laboratory samples. For subjects who discontinued, Month 6 data is imputed using the subject's last nonmissing, postbaseline value in the open-label period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/RIS</title>
            <description>Open-label Period. Subjects in the double-blind placebo group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
          <group group_id="O2">
            <title>Ris Low Dose/RIS</title>
            <description>Open-label Period. Subjects in the double-blind risperidone low dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
          <group group_id="O3">
            <title>Ris High Dose/RIS</title>
            <description>Open-label Period. Subjects in the double-blind risperidone high dose group who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance (IR) at 6 Months</title>
          <description>Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.</description>
          <population>All subjects with at least one dose of study medication in the open label phase and both double-blind baseline and at least one open-label period fasting laboratory samples. For subjects who discontinued, Month 6 data is imputed using the subject's last nonmissing, postbaseline value in the open-label period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="2.67"/>
                    <measurement group_id="O2" value="0.36" spread="0.89"/>
                    <measurement group_id="O3" value="0.75" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double-blind period: 6 weeks. Open-label period: 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Double-blind Period. Oral solution for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Risperidone Low Dose</title>
          <description>Double-blind Period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Risperidone High Dose</title>
          <description>Double-blind Period. Risperidone oral solution 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg) for 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Open-label Risperidone</title>
          <description>Subjects who continued into open-label risperidone period. Risperidone oral solution 0.125 mg (if &lt;45 kg) or 0.175 mg (if &gt;=45 kg) for 3 days, 0.25 mg tablet on Day 4, flexible dose in 0.25 mg or 0.5 mg increments every 2 weeks, as clinically indicated, to a maximum dose of 1.25 mg (if &lt;45 kg) or 1.75 mg (if &gt;=45 kg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>609 730 2317</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

